About 60 Degrees Pharmaceuticals Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://60degreespharma.com/
Frequently Asked Questions
What is the 52-week range for SXTP?
The 52-week high is $8.62 and the 52-week low is $0.8399.
What is the P/E ratio for SXTP?
The P/E ratio data is currently unavailable.
What is the dividend yield for SXTP?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -211.48%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -667.41%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.62.
Analyst Recommendation Trends
Wall Street analyst consensus for SXTP over the last few months:
Latest SXTP News
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ORLANDO, FL / ACCESS Newswire / October 2, 2026 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP; SXTPW) and Exyn Technologies Inc.
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier. WASHINGTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector
60 Degrees Pharmaceuticals To Present Data On Interim Analysis From Its Clinical Trial Of Tafenoquine On Oct. 6
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced
60 Degrees Pharmaceuticals Says It Submitted Statement Of Interest To FDA For Commissioner's National Priority Voucher For ARAKODA In Babesiosis; DSMB Interim Analysis Of Phase 2 Trial Scheduled October 1, Targets sNDA Submission In March-April 2027
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001946563/000121390026099702/ea0305442-8k_60degree.htm
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-12 | DOW GEOFFREY S | +7,350 | $1.3784 | $10,131 |
| 2025-12-15 | DOW GEOFFREY S | +9,670 | $0.8024 | $7,759 |
| 2025-12-11 | DOW GEOFFREY S | +3,613 | $0.9184 | $3,318 |
| 2025-12-10 | DOW GEOFFREY S | +9,350 | $0.9504 | $8,886 |